Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.


Translational Research Office
Boundary Brook House
Churchill Drive

Caroline Jenkins

Translational Research Manager

I joined the Translational Research Office (TRO) in October 2019 on a 12 month secondment from the University's Research Services, Medical Sciences team. During my secondment to the TRO I will focus primarily on supporting the progression of Wellcome-funded translational research projects.

In Research Services I have spent ten years working in the Research Contracts team. I have considerable experience in the negotiation of research-related agreements, liaising with funders and collaborators from all sectors and facilitating a diverse portfolio of clinical and pre-clinical research for over twenty different departments within the Medical Sciences Division. For several years I have line-managed a team of research contracts specialists alongside maintaining my own caseload.

Prior to that I worked in the University's technology transfer company, Isis Innovation Ltd (now known as Oxford University Innovation Ltd), in the Consulting Services team. Here I promoted the depth and breadth of the University's academic expertise through business development activities and matched University experts to commissioned consultancy projects, often creating knowledge exchange opportunities for academics who had never consulted before. I also managed the contractual negotiation of the consultancy agreements.

My background was at the lab bench: My postdoc was in the University's Cardiovascular Medicine department, where I investigated the role of polycomb proteins in mammalian cardiac development. My DPhil was split between the Weatherall Institute of Molecular Medicine and the Sir William Dunn School of Pathology. I studied a novel mechanism that upregulated AP-1-dependent transcription in fission yeast that resulted in multi-drug resistance.